Provided by Tiger Trade Technology Pte. Ltd.

AKESO

93.600
-1.450-1.53%
Volume:7.15M
Turnover:672.65M
Market Cap:86.21B
PE:-65.00
High:96.000
Open:95.050
Low:93.400
Close:95.050
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:0.46
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.440
ROE:-13.59%
ROA:-4.57%
PB:8.70
PE(LYR):-65.00
PS:21.39

Loading ...

Akeso Advances IO2.0 + Adc2.0 Strategy: First Patient Dosed in Phase Ii Study of Trop2/Nectin-4 Bispecific ADC (Ak146d1) Combined with Ivonescimab in Breast Cancer

THOMSON REUTERS
·
Aug 10

HK Movers | Pharma Stocks Jump With Viva Biotech up 15%, WuXi XDC, WuXi Biologics up 6%

Tiger Newspress
·
Aug 10

Movement Alert|AKESO Rises 4% in Regular Trading, Multiple International Registrational Clinical Studies Advancing Rapidly

Market Focus
·
Aug 10

Biotech ETF Gains Over 5% as Leading Innovators Report Strong Earnings and Global Supply Chain Remains Robust

Stock News
·
Aug 07

Movement Alert|AKESO Rises 3.28% in Regular Trading, Ivonescimab Plus Enfortumab Vedotin Phase II/III Registrational Study Initiated for First-Line UC

Market Focus
·
Aug 07

Movement Alert|AKESO Rises 3.04% in Regular Trading, Innovative Drug Sector Collectively Strengthens Ahead of Major Academic Conferences

Market Focus
·
Aug 05

Akeso (SEHK:9926) Dosed Its First AK138D1 Patient, Is The 47% Undervalued View Too Bullish?

Simply Wall St.
·
Aug 03

China's domestic innovative drugs set for overseas revenue breakthrough as policy support strengthens

Stock News
·
Jul 31

Movement Alert|AKESO Falls 3.29% in Regular Trading, Share Option Exercise Price Inversion Compounds Biotech Sector Weakness

Market Focus
·
Jul 30

China's Biotechnology Success Meets Increasing US Scrutiny, Analytics Firm Says

MT Newswires Live
·
Jul 29

Movement Alert|AKESO Falls 3.04% in Regular Trading, Share Option Grant Sparks Dilution Concerns Amid Biotech Sector Pullback

Market Focus
·
Jul 28

Akeso Doses First Patient in Phase Ib/II NSCLC Trial of HER3 ADC Ak138d1 with Ivonescimab

Reuters
·
Jul 28

Nomura Adjusts Akeso's Price Target to HK$138.29 From HK$142.50, Keeps at Buy

MT Newswires Live
·
Jul 27

AKESO (09926) Grants 3,603,500 Share Options and 1,648,500 Restricted Share Units

Stock News
·
Jul 26

Akeso Grants 3,603,500 Share Options at HK$ 99.5 Exercise Price Under Employee Incentive Plan

Reuters
·
Jul 26

Akeso (SEHK:9926) Partners With MSK, Is The Discount To Fair Value Justified?

Simply Wall St.
·
Jul 24

Movement Alert|AKESO Falls 3.11% in Regular Trading, Profit-Taking After Two-Day Rally Amid Sector Pullback

Market Focus
·
Jul 24

Movement Alert|AKESO Rises 4.15% in Regular Trading, Ivonescimab Global Phase III OS Data Continues to Improve with New Renal Cancer Collaboration

Market Focus
·
Jul 23

How Akeso’s IO 2.0 Bispecific Push At Akeso (SEHK:9926) Has Changed Its Investment Story

Simply Wall St.
·
Jul 23

Movement Alert|Akeso Rises 4.39% in Regular Trading, Novel Bispecific ADC Completes First Patient Dosing in Phase II NSCLC Study

Market Focus
·
Jul 22